Irritable bowel syndrome clinical trial design: future needs (Q33788481)

29 July 2017

1 reference

title

Irritable bowel syndrome clinical trial design: future needs (English)

1 reference

29 July 2017

main subject

irritable bowel syndrome

1 reference

Hawkey CJ

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

American Journal of Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

107

1 reference

29 July 2017

issue

5A

1 reference

29 July 2017

page(s)

98S-102S

1 reference

Controlled treatment trials in the irritable bowel syndrome: a critique.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Towards positive diagnosis of the irritable bowel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

A patient questionnaire to identify bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Diagnostic value of the Manning criteria in irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Irritable bowel syndrome: pathogenesis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

A scoring system for diagnosing irritable bowel: time to try again?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Daily gastrointestinal symptoms in women with and without a diagnosis of IBS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Clinical and laboratory assessments in rheumatoid arthritis and osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Bran supplementation in the treatment of irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

The short-term natural history of irritable bowel syndrome: a time-series analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Clinical trials. How should they be designed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Effects of desipramine on irritable bowel syndrome compared with atropine and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Cimetidine on-demand in dyspepsia. Experience with randomized controlled single-subject trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Histamine H2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

Eradication of Helicobacter pylori should be pivotal in managing peptic ulceration. Eradication largely prevents relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900087-X

10.1016/S0002-9343(99)00087-X

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference